Japan Nuclear Medicine Market to Reach US$ 2,543.2 Million by 2031 Growing at 21.2% CAGR with Diagnostic Nuclear Medicine Holding 65% Share Led by GE HealthCare, Siemens Healthineers, Fujifilm Toyama Chemical and Canon Medical Systems

The Japan Nuclear Medicine Market reached US$ 550.3 million in 2023 and is expected to grow to around US$ 2,543.2 million by 2031, expanding at a CAGR of approximately 21.2 % from 2024 to 2031 as demand for advanced diagnostic and therapeutic nuclear imaging solutions rises nationwide.

Growth is supported by increasing demand across key applications such as oncology diagnostics, cardiology imaging, neurological scans, and targeted radionuclide therapies, driven by the rising incidence of cancer and cardiovascular diseases, a rapidly ageing population with higher healthcare needs, ongoing investments in medical R&D, and the adoption of cutting-edge PET and SPECT imaging systems. With Japan's well-established healthcare infrastructure and strong domestic research collaborations fostering innovation in radiopharmaceuticals and precision diagnostics, nuclear medicine remains vital for early disease detection, treatment planning, and improved clinical outcomes, fostering broad adoption across hospitals, diagnostic centres, and specialty clinics nationwide.

Download your exclusive sample report today (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/japan-nuclear-medicine-market?sindhuri

Japan Nuclear Medicine Market: Competitive Intelligence
GE HealthCare, FUJIFILM Toyama Chemical Co. Ltd. (Fujifilm), Siemens Healthineers AG, Bracco Imaging S.p.A., CANON MEDICAL SYSTEMS CORPORATION, Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd), ATOX CO., Ltd., IBA Radiopharma Solutions, JFE Engineering Corporation, Koninklijke Philips N.V., and others.

The Japan Nuclear Medicine Market is strongly driven by leading players such as GE HealthCare, Fujifilm Toyama Chemical, Siemens Healthineers, Bracco Imaging, and Canon Medical Systems, who provide advanced nuclear imaging systems (PET and SPECT), radiopharmaceuticals, and integrated diagnostic and therapeutic solutions for oncology, cardiology, neurology, and other clinical applications. Nuclear medicine uses radioactive tracers to visualize physiological processes, enabling early disease detection, personalized diagnostics, and targeted therapies, particularly in cancer and cardiovascular care. Japan's advanced healthcare infrastructure, high life expectancy, and rising prevalence of chronic diseases underpin increasing adoption of molecular imaging technologies. The market was valued at approximately USD 550.3 million in 2023, and is forecasted to grow robustly through 2031 driven by demand for precision diagnostics and innovation in radiopharmaceuticals.
These companies' complementary strengths comprehensive imaging equipment portfolios and clinical integration from GE HealthCare and Siemens Healthineers; localized radiopharmaceutical expertise and hybrid imaging innovation from Fujifilm and Bracco; advanced diagnostic systems and workflow solutions from Canon Medical and Philips; and specialist nuclear medicine product development from Nihon Medi-Physics, ATOX, IBA Radiopharma, and JFE Engineering enhance competitive positioning in Japan's market. Strategic focus areas include advancement of PET/SPECT imaging technologies and tracers, theranostics development (combined diagnostic and therapeutic radiopharmaceuticals), partnerships with healthcare providers and research institutions, expanded clinical applications across oncology and cardiovascular disease, and improved access through expanded facility networks and workforce training, strengthening competitiveness in precision imaging and targeted care delivery nationwide.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/japan-nuclear-medicine-market?sindhuri

Recent Key Developments - Japan
✅ June 2025: Japan's Ministry of Health, Labour and Welfare (MHLW) updated reimbursement codes to increase coverage for advanced nuclear medicine procedures, including PET/CT and SPECT-based molecular imaging, aimed at improving early cancer diagnosis and treatment monitoring.
✅ May 2025: Canon Medical Systems expanded its SPECT and PET/CT portfolio with AI-assisted reconstruction and quantification tools, enhancing diagnostic accuracy and workflow efficiency in Japanese hospitals and cancer centers.
✅ 2025 (Industry Forum): At the 2025 Japan Society of Nuclear Medicine Annual Meeting in Tokyo, major vendors and clinicians showcased innovations in theranostics (diagnostic + therapeutic radiopharmaceuticals), including progress in radioisotope-linked cancer therapies.

Recent Key Developments - United States & North America (Global Context)
✅ 2025: Leading nuclear medicine manufacturers such as GE HealthCare and Siemens Healthineers announced new AI-enhanced PET and SPECT systems that are being localized for the Japanese market boosting image quality and workflow across clinical settings.
✅ June 2025: FDA approvals of next-generation diagnostic radiopharmaceuticals for prostate cancer and neurodegenerative disease are expanding the global tracer landscape, with Japanese regulatory pathways expected to follow with local submissions.
✅ 2025-2026: U.S. clinical standards and guideline updates for PET imaging in oncology are influencing Japanese practice patterns, particularly in lymphoma and metastatic prostate cancer management.

Recent Key Developments - Europe & Other Regions
✅ 2025: European Medicines Agency (EMA) approvals for novel theranostic agents (e.g., PSMA-targeted therapies) are accelerating global adoption, and Japanese regulatory bodies are evaluating data for potential local authorization.
✅ Late 2025: Collaborative research between Japan and European nuclear medicine networks is advancing comparative effectiveness studies of PET tracers in Alzheimer's disease and cardiac sarcoidosis.
✅ 2025: European hospitals' adoption of AI support for quantitative nuclear imaging informs technology expectations in Japanese radiology and nuclear medicine departments.

Recent Key Developments - Product & Technology Innovation
✅ AI-Assisted Image Enhancement: Multiple nuclear medicine systems now embed AI-driven reconstruction and lesion detection algorithms, improving sensitivity and reducing scan time for PET and SPECT studies.
✅ Theranostics Advances: Progress in theranostic pairs (diagnostic and therapeutic isotopes like Lu-177 and Ac-225) for neuroendocrine tumors and prostate cancer is expanding nuclear medicine beyond imaging into targeted treatment.
✅ Digital PET & Time-of-Flight Enhancements: Next-generation digital PET systems with improved time-of-flight performance are being deployed in major Japanese facilities, enabling higher resolution imaging with lower radiation dose.

✅ 1. M&A / Strategic Developments
Strategic Partnerships & Portfolio Expansion
Philips & Canon Medical Systems Collaboration (2025-2026) Strengthened cooperation for integrated nuclear medicine solutions in Japan, combining Philips' software and quantitative imaging tools with Canon Medical PET/CT and SPECT/CT hardware platforms to enhance diagnostic accuracy and workflow efficiency.
Siemens Healthineers Japan Expansion Continued expansion of nuclear medicine services and training partnerships with local hospital networks to promote adoption of advanced PET/MR systems as well as digital image reconstruction and AI-assisted quantification tools.
Fujifilm Japan Strategic Focus Fujifilm invested in bolstering its nuclear medicine portfolio by integrating high-resolution detectors and AI technologies into its hybrid imaging hardware and nuclear medicine image processing software to increase clinical precision and operational performance.

✅ 2. New Product Launches & Technology Developments
Advanced PET/CT and PET/MR Systems
» Late 2025: Canon Medical Systems Japan released an upgraded PET/CT system with enhanced Time-of-Flight (TOF) and improved sensitivity, enabling better lesion detectability at reduced dose exposures significant for oncology and neurology imaging.
» Philips Vereos Digital PET/CT Enhancements (2025) Launched software upgrades improving quantification analytics and clinical workflow support tailored for Japanese clinical protocols.
Next-Gen Radiopharmaceuticals
» Strong research and regulatory focus in Japan on novel radiotracers for oncology and neurodegenerative diseases:
» Amino acid and PSMA-targeted tracers are advancing through late-phase clinical evaluation to support precision oncology diagnosis and therapy monitoring.
»Tau and amyloid PET agents continue to be used in clinical research and early Alzheimer's disease detection workflows.
Hybrid Imaging Software
Vendors introduced AI-powered reconstruction, quantification, and motion correction software for nuclear medicine imaging, improving consistency and reproducibility in diagnosis particularly in PET/MR workflows.

✅ 3. R&D & Innovation Trends
AI-Assisted Nuclear Medicine
Research activity in Japan increasingly integrates AI/ML tools for automated lesion detection, organ segmentation, and longitudinal disease progression analysis elevating the diagnostic utility of PET/CT and PET/MR.
Quantitative Nuclear Biomarkers
R&D emphasis on standardized quantitative PET biomarkers enables objective assessment of treatment response (e.g., SUV harmonization), moving toward precision medicine workflows in oncology and inflammatory disease imaging.
Radiopharmaceutical Development
Japanese academic and industrial research programs are advancing next-generation targeted radiopharmaceuticals for both diagnostic and theranostic applications, such as neuroendocrine, prostate, and lymphoma imaging.
Theranostics Integration
Growth in theranostic frameworks pairing diagnostic nuclear agents with therapeutic radioisotopes is shaping integrated clinical care models. Japan's regulatory frameworks support clinical research in these dual-purpose agents.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=japan-nuclear-medicine-market?sindhuri

Segments Covered in the Japan Nuclear Medicine Market:
By Product Type
The market is segmented into Diagnostic Nuclear Medicine 65% and Therapeutic Nuclear Medicine 35%, with diagnostic nuclear medicine dominating due to high adoption of PET and SPECT imaging for early disease detection. Radiopharmaceuticals and imaging systems contribute significantly to this segment. Therapeutic nuclear medicine is growing steadily with increasing use of targeted radionuclide therapies for cancer and thyroid disorders. Rising demand for precision diagnostics and minimally invasive treatments drives product adoption.
By Procedural Volume Assessment
Procedural volumes include Oncology 50%, Cardiology 25%, Neurology 15%, and Others 10%, with oncology dominating due to high cancer prevalence and increasing PET/CT utilization for tumor detection, staging, and monitoring. Cardiology procedures are widely used for myocardial perfusion imaging. Neurology applications are growing for Alzheimer's disease and other neurodegenerative disorder assessments. Expansion of advanced imaging facilities supports procedural growth.
By Application
Applications include Oncology 45%, Cardiology 25%, Neurology 15%, Thyroid Disorders 10%, and Others 5%, with oncology dominating due to increasing cancer screening programs and adoption of radioligand therapies. Cardiology remains significant for ischemic heart disease diagnostics. Neurology is expanding with rising geriatric population and dementia cases. Thyroid-related nuclear imaging and therapy maintain steady demand.
By End-User
End-users include Hospitals 60%, Diagnostic Imaging Centers 25%, Specialty Clinics 10%, and Others 5%, with hospitals dominating due to availability of advanced imaging systems, cyclotrons, and trained nuclear medicine specialists. Diagnostic imaging centers are growing with rising outpatient imaging demand. Specialty clinics focus on targeted radionuclide therapies and thyroid treatments.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.